Pulse Biosciences (PLSE) Stock Price, News & Analysis

Company Overview

Pulse Biosciences, Inc. is a medical technology company focused on the development and commercialization of novel bioelectric therapies using its proprietary Nano-Pulse Stimulation (NPS) platform. The company’s technology delivers ultra-short electrical pulses that create transient nanopores in cell membranes, triggering programmed cell death without the use of heat or chemical agents. This non‐thermal approach aims to provide precise tissue ablation with minimal collateral damage, making it applicable across a range of dermatological and oncological indications.

The company’s primary commercial product, the CellFX® System, is designed to treat benign skin lesions and select aesthetic dermatology applications. CellFX has received regulatory approvals in multiple regions for the clearance of non‐cancerous dermatologic conditions, and clinical studies are ongoing to expand its use in early-stage skin cancers. In parallel, Pulse Biosciences is advancing its oncology pipeline, known as PulseTx®, which leverages NPS technology to target internal tumors and potentially enhance the body’s immune response against cancer cells.

Founded in 2013 and headquartered in Hayward, California, Pulse Biosciences has established a commercial presence in North America and is pursuing regulatory clearances in Europe and Asia-Pacific markets. The company collaborates with leading academic institutions and research centers to validate new clinical applications for its NPS platform. Strategic partnerships and investigator-initiated trials are central to its efforts to broaden the technology’s reach into both aesthetic and therapeutic segments.

Under the leadership of CEO Vadim Gliner, Pulse Biosciences emphasizes innovation and science-driven commercialization. The executive team comprises veterans in medical device development and life sciences, supporting the company’s goal of bringing minimally invasive bioelectric therapies from the laboratory to clinical practice. Pulse Biosciences continues to invest in research and development, aiming to expand its product portfolio and address unmet medical needs in dermatology and oncology.

Key Stats

• Today's Range: $15.07 to $15.84
• 50-Day Range: $14.80 to $17.93
• 52-Week Range: $13.50 to $25.00
• Volume: 210,216 shs
• Average Volume: 173,990 shs
• Market Capitalization: $1.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

Pulse Biosciences Stock Analysis - MarketRank™

Pulse Biosciences scored higher than 56% of companies evaluated by MarketBeat, and ranked 257th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pulse Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pulse Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Pulse Biosciences has a P/B Ratio of 8.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.84% of the float of Pulse Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Pulse Biosciences has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Pulse Biosciences has recently increased by 2.04%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulse Biosciences does not currently pay a dividend.

Dividend Growth

Pulse Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

19.84% of the float of Pulse Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Pulse Biosciences has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Pulse Biosciences has recently increased by 2.04%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pulse Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $246,000.00 in company stock.

Percentage Held by Insiders

71.50% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.95% of the stock of Pulse Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PLSE Stock Analysis - Frequently Asked Questions

How have PLSE shares performed this year?

Pulse Biosciences' stock was trading at $17.41 at the beginning of the year. Since then, PLSE stock has decreased by 13.3% and is now trading at $15.10.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc (NASDAQ:PLSE) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.25) EPS for the quarter.
Read the conference call transcript.

When did Pulse Biosciences IPO?

Pulse Biosciences (PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

How do I buy shares of Pulse Biosciences?

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulse Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PLSE
• CIK: 1625101
• Web: www.pulsebiosciences.com
• Phone: (510) 906-4600
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pulse Biosciences: $22.00
• High Price Target: $22.00
• Low Price Target: $22.00
• Potential Upside/Downside: +45.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -68.44%
• Return on Assets: -58.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.58
• Quick Ratio: 15.58

Sales & Book Value

• Annual Sales: $700 thousand
• Price / Sales: 1,451.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.87 per share
• Price / Book: 8.07

Miscellaneous

• Outstanding Shares: 67,270,000
• Free Float: 19,173,000
• Market Cap: $1.02 billion
• Optionable: Optionable
• Beta: 1.56